<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01009021</url>
  </required_header>
  <id_info>
    <org_study_id>NSAID-PRP</org_study_id>
    <nct_id>NCT01009021</nct_id>
  </id_info>
  <brief_title>Oral Diclofenac for Retinal Photocoagulation in Diabetic Retinopathy</brief_title>
  <official_title>Analgesic Effectiveness of Potassium Diclofenac for Retinal Photocoagulation in Patients With High-risk Proliferative Diabetic Retinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate the analgesic effect of oral potassium diclofenac
      in patients with proliferative diabetic retinopathy submitted to retinal photocoagulation.

      Two groups of patients were followed and the effect of the treatment (diclofenac plus laser)
      was compared to placebo (placebo plus laser). Pain associated with treatment was recorded
      using a Visual Analog Scale 15 minutes after the procedure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain recorded using a Visual Analog Scale</measure>
    <time_frame>15 minutes after the procedure</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Placebo first (scheme 2)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>scheme 2 patients (n=15) received a brown-coated tablet of saccharine (placebo) 45 minutes before the first PRP episode [placebo treatment episode (PTE)] at baseline to the right eye and two weeks after received one 50 mg tablet of potassium diclofenac 45 minutes before the second PRP episode [diclofenac treatment episode (DTE)] to the left eye</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diclofenac first (scheme 1)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>scheme 1 patients (n=15) received one 50 mg tablet of potassium diclofenac 45 minutes before the first PRP episode [diclofenac treatment episode (DTE)] at baseline to the right eye and two weeks after received an identical brown-coated tablet of saccharine (placebo) 45 minutes before the second PRP episode [placebo treatment episode (PTE)] to the left eye</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>potassium diclofenac</intervention_name>
    <description>potassium diclofenac 50 mg, one tablet 45 minutes before laser treatment</description>
    <arm_group_label>Placebo first (scheme 2)</arm_group_label>
    <arm_group_label>Diclofenac first (scheme 1)</arm_group_label>
    <other_name>Cataflan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1)high-risk proliferative diabetic retinopathy in both eyes

        Exclusion Criteria:

          -  1)history of prior laser treatment or vitrectomy; 2) allergy to non-steroidal
             anti-inflammatory drugs; 3) any condition affecting comprehension of VAS pain score
             test; 4) Contra-indications for diclofenac use such as pregnancy, bleeding disorders,
             asthma, or renal failure; 5) use of any analgesic drug for the last 24 hours.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ribeirão Preto School of Medicine Clinics Hospital - USP</name>
      <address>
        <city>Ribeirão Preto</city>
        <state>São Paulo</state>
        <zip>14049-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2009</study_first_submitted>
  <study_first_submitted_qc>November 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2009</study_first_posted>
  <last_update_submitted>November 5, 2009</last_update_submitted>
  <last_update_submitted_qc>November 5, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Rodrigo Jorge</name_title>
    <organization>University of Sao Paulo Professor</organization>
  </responsible_party>
  <keyword>pain</keyword>
  <keyword>retinal photocoagulation</keyword>
  <keyword>potassium diclofenac</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

